VECIMA-NETWORKS
1.5.2024 13:31:31 CEST | Business Wire | Press release
Vecima Networks Inc. (TSX: VCM) will showcase its open, flexible, and interoperable access and video portfolios, including 10G PON fiber access, the new Entra Virtual Cable Modem Termination system (vCMTS), Remote PHY (R-PHY) and market-share-leading Remote MACPHY (R-MACPHY) solutions, and next-generation video delivery, including MediaScale Open Content Delivery Network (CDN)™, and Dynamic Content & Ad Insertion.
Technologies to be on display
The recently announced Entra® vCMTS, part of Vecima’s Entra Cloud™ platform of open, interoperable, cloud-native applications, is built from the ground up to provide the scalability and throughput required for DOCSIS® 4.0 services. It features an open, cloud-native design that is fully containerized and dynamically scalable for operators of every size at market-leading densities.
Built on field-proven Vecima DOCSIS® technology, it is designed to maximize performance while minimizing space, power, and cost. It is interoperable with Vecima’s widely deployed R-PHY Devices (RPDs) and Vecima is fully committed to interoperability with other vendors.
The Entra® SC-1D Entra Access Node offers R-MACPHY in a compact, European form factor. Part of Vecima’s Distributed Access Architecture (DAA) solution that’s deployed in Europe, the SC-1D enables operators to deploy gigabit broadband and new services to residential subscribers and businesses. In addition, moving to DAA delivers sustainability through digitization, enabling substantial energy savings. Dell’Oro Group recently named Vecima as the global revenue share leader in R-MACPHY devices.
The Entra® EN2112 R-PHY Access Node is a high-density, compact, two-port node that’s interoperable with third-party converged cable access platform (CCAP) cores and vCMTS, creating an open, flexible DAA ecosystem. Supporting architectures that push fiber deeper into the network, the EN2112 allows operators to optimize existing hybrid fiber coax (HFC) network capacity and deliver increased bandwidth to subscribers.
Named by Dell’Oro Group as the global market share leader for Remote Optical Line Terminals (R-OLTs) for the third year, Vecima expands its fiber access portfolio with a flexible, compact, and powerful shelf-based platform that supports all predominantly deployed Passive Optical Network (PON) variants. The Entra® EXS1610 All-PON™ Shelf allows customers to selectively deploy fiber to the home in any market hub or outside plant cabinet deployment, allowing maximum flexibility to deploy fiber access solutions based on specific subscriber need. In addition, the EXS1610 interoperates seamlessly with 10 different optical network unit (ONU) vendors, enabling operators to independently select the ONU vendor of their choice.
We will also show MediaScale™ Content Distribution solutions, including Open CDN for high-quality, congestion-free streaming that’s more cost-effective and efficient, and Dynamic Content with Ad Insertion for highly targeted ads and more value per impression.
With MediaScale Open CDN, content owners cut congestion, public CDN costs, and latency, and service providers can monetize the content they’re already delivering. Open CDN delivers video streaming at the highest available bitrates, with zero rebuffering and at an energy-efficient 235 Mbps per watt, while providing the lowest cost of ownership available.
Service providers can gain control over content with the MediaScale Dynamic Content & Ad Insertion solution which supports content rights, blackouts, and advertising. By manipulating content at the edge of the network, operators can deliver more efficient, personalized video content and more opportunities to monetize that content with targeted, higher-value ads.
Vecima speakers at ANGA COM
Vecima’s Chris Busch, Principal Access Architect Office of CTO, will speak on “Low Latency in Fiber and HFC Networks” on Tuesday, May 14.
Quotes from Vecima executives attending ANGA COM
“Vecima continues to expand its European footprint, bringing proven, market-leading solutions for access and IP video to our customers,” said John Ruwe, Vice President of EMEA Sales at Vecima. “With our valued partners in the region, we’re helping operators build the fiber, cable, and video networks that open up new services for their subscribers.”
“We meet operators where they are, offering multiple options to evolve their networks to meet the broadband demands of the future,” said Ryan Nicometo, Senior Vice President and General Manager, Video & Broadband Solutions at Vecima. “At Vecima, we take an open, interoperable approach that gives operators ultimate flexibility to choose the path that takes them to the future.”
Visit Vecima Networks at ANGA COM 2024
May 14-16 Cologne, Germany
Koelnmesse Hall 8, Stand A20
To schedule a meeting with the Vecima team, contact us at sales@vecima.com.
Media and industry analysts, please contact bernadette.dunn@vecima.com.
About Vecima Networks
Vecima Networks Inc. (TSX: VCM) is leading the global evolution to the multigigabit, content-rich networks of the future. Our talented people deliver future-ready software, services, and integrated platforms that power broadband and video streaming networks, monitor and manage transportation, and transform experiences in homes, businesses, and everywhere people connect. We help our customers evolve their networks with cloud-based solutions that deliver ground-breaking speed, superior video quality, and exciting new services to their subscribers. There is power in connectivity – it enables people, businesses, and communities to grow and thrive.
Learn more at vecima.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240501888729/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom